In line with our results, two large clinical trials, in which NAFLD was an established comorbidity among the enrolled patients, have recently shown a dose-dependent reduction of serum ALT and high-sensitivity C-reactive protein values after treatment with Semaglutide [38]. Here, CRP is linked to metabolic dysfunction-associated steatotic liver disease.